SPOTlight on GLOW

The GLOW randomized double-blind phase 3 trial(1) shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junct...

Descripción completa

Detalles Bibliográficos
Autores principales: Derks, Sarah, van Laarhoven, Hanneke W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591046/
https://www.ncbi.nlm.nih.gov/pubmed/37852180
http://dx.doi.org/10.1016/j.xcrm.2023.101233
Descripción
Sumario:The GLOW randomized double-blind phase 3 trial(1) shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Ejemplares similares